NEW ZEALAND GAZETTE, No. 15 — 12 FEBRUARY 2015

From 12 February 2015:

The following class of persons ("vocational medical practitioners") may prescribe methylphenidate products for a patient under his or her care for the corresponding conditions:

• Medical practitioners with a vocational scope of practice of paediatrics or psychiatry, registered with the Medical Council of New Zealand under the Health Practitioners Competence Assurance Act 2003, for the treatment of Attention Deficit and Hyperactivity Disorder (ADHD); or

• medical practitioners with a vocational scope of practice of internal medicine, registered with the Medical Council of New Zealand under the Health Practitioners Competence Assurance Act 2003, for the treatment of narcolepsy; or

• medical practitioners with a vocational scope of palliative medicine, registered with the Medical Council of New Zealand under the Health Practitioners Competence Assurance Act 2003, for use in palliative care treatment.

Any other medical practitioner registered with the Medical Council of New Zealand ("registered medical practitioner"), or nurse practitioner registered with the Nursing Council of New Zealand practising within their area of practice ("nurse practitioner"), may only prescribe methylphenidate products when acting on the written recommendation of one of the vocational medical practitioners described above, for the conditions specified.

Supply

From 12 February 2015:

The following class of persons may supply methylphenidate products in the following circumstances:

Any pharmacist registered with the Pharmacy Council of New Zealand under the Health Practitioners Competence Assurance Act 2003, in the course of his or her employment as a pharmacist, may supply methylphenidate products pursuant to a prescription issued by:

• a registered medical practitioner with a vocational scope of practice of paediatrics, psychiatry, internal medicine or palliative medicine, when prescribing for the conditions specified in this Schedule; or

• any other registered medical practitioner or nurse practitioner, when acting on the written recommendation of one of the vocational medical practitioners specified in this Schedule, with the recommendation endorsed on the prescription.

Administration

From 12 February 2015:

Any person who is caring for a patient, for whom a methylphenidate product has been prescribed by any of the medical practitioners or nurse practitioners described in this Schedule, may administer the product to that patient in accordance with the prescribed directions for use.

Dated at Wellington this 5th day of February 2015.

MICHAEL HAYNES, Team Leader, Medicines Control, Ministry of Health.

2015-go760

Notice of Application to Register a Trade Name Product (Notice No. MPI 458)

Maree Zinzley, Manager Approvals Operations of the Ministry for Primary Industries (MPI), acting under delegated authority from the Director-General of MPI, gives notice, under section 14(1) of the Agricultural Compounds and Veterinary Medicines Act 1997 ("the Act"), that the following application has been made to register a trade name product under section 9(1) of the Act:

Trade Name: Advance Gold

Reference: P9164

Active Ingredient and Concentration:

Salicylic acid 122.7g/L

Formulation Type: Soluble liquid

General Use Claim: